Global Single-Domain Heavy Chain Antibody Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Single-Domain Heavy Chain Antibody market size was valued at US$ 1152 million in 2025 and is forecast to a readjusted size of US$ 3367 million by 2032 with a CAGR of 16.5% during review period.
Single-Domain Heavy Chain Antibody refers to a small antibody molecule in which a single variable domain can recognize and bind to an antigen. In industry usage, it is more commonly described as Single-Domain Antibody, VHH Antibody, or sdAb, covering camelid-derived VHH antibodies, shark-derived VNAR antibodies, and engineered human VH single-domain antibodies. Compared with conventional full-length IgG antibodies, these molecules are smaller, structurally simpler, and generally more stable, with good tissue penetration and strong engineering flexibility. They can be used in therapeutic biologics, diagnostic reagents, research antibodies, molecular imaging, cell therapy binding domains, and bispecific or multispecific antibody development. Key upstream inputs include antigen proteins or peptides, immunized animal resources, phage display libraries, yeast display libraries, synthetic antibody libraries, expression vectors, host cells, culture media, chromatography resins, conjugation reagents, and protein purification consumables. Major downstream customers include pharmaceutical companies, biotechnology companies, diagnostic companies, research service providers, universities, research institutes, and hospital laboratories. The global industry gross margin in 2025 is estimated at approximately 55%?75%.
The single-domain heavy chain antibody market is still in a stage of continuous platform validation and accelerating commercialization, with lower maturity than the conventional monoclonal antibody market but higher innovation activity. VHH, VNAR, and engineered human VH antibodies are gaining application momentum due to their small molecular size, good stability, engineering flexibility, and stronger tissue penetration. They are increasingly used in therapeutic biologics, diagnostic reagents, research antibodies, molecular imaging, and cell therapy engineering. Current market participants include innovative drug developers with proprietary platforms and clinical pipelines, as well as CROs and reagent companies providing antibody discovery, screening, humanization, affinity maturation, and protein expression services. The industry remains both platform-driven and project-driven.
From the demand side, therapeutic applications represent the highest long-term value area, especially in tumor immunology, immune-mediated inflammatory diseases, rare diseases, infectious diseases, and central nervous system delivery. Compared with conventional antibodies, single-domain antibodies are well suited for bispecific, multispecific, multivalent, and fusion protein formats, and can also serve as targeting domains for CAR-T, TCR-T, and other cell therapy products. At the same time, research and diagnostic applications provide a more stable demand base. Single-domain antibodies are well adapted for immunoassays, tissue staining, structural biology, live-cell imaging, and protein localization studies, supporting commercial demand before broader therapeutic commercialization.
Future development will focus on fully human platforms, multispecific design, half-life extension, AI-assisted screening, and high-throughput antibody library construction. The small size of single-domain antibodies is both an advantage and a limitation, as it can lead to faster in vivo clearance. As a result, albumin binding, Fc fusion, multivalent formatting, and PEGylation will remain important half-life extension strategies. With the integration of AI protein design, deep sequencing, synthetic antibody libraries, phage display, and yeast display technologies, discovery efficiency and developability assessment are expected to improve. Companies with strong capabilities in difficult-target screening, multi-format antibody engineering, CMC scale-up, and clinical translation will be better positioned in high-value therapeutic programs.
The main barriers include long clinical validation cycles, intellectual property constraints, immunogenicity control, manufacturing scale-up, and increasing service-level competition. Some VHH and VNAR molecules originate from non-human species, requiring sufficient humanization and immunogenicity assessment before therapeutic development. The short half-life associated with small molecular size also requires additional engineering, increasing R&D complexity. Meanwhile, as more CROs, research reagent suppliers, and platform companies enter VHH and sdAb discovery services, early-stage service pricing pressure may intensify. Overall, single-domain heavy chain antibodies are unlikely to simply replace conventional monoclonal antibodies, but they will continue to expand in differentiated scenarios such as difficult targets, multispecific formats, tissue penetration, imaging diagnostics, and cell therapy engineering.
This report is a detailed and comprehensive analysis for global Single-Domain Heavy Chain Antibody market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Single-Domain Heavy Chain Antibody market size and forecasts, in consumption value ($ Million), 2021-2032
Global Single-Domain Heavy Chain Antibody market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Single-Domain Heavy Chain Antibody market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Single-Domain Heavy Chain Antibody market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Single-Domain Heavy Chain Antibody market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Single-Domain Heavy Chain Antibody product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Single-Domain Heavy Chain Antibody, with revenue, gross margin, and global market share of Single-Domain Heavy Chain Antibody from 2021 to 2026.
Chapter 3, the Single-Domain Heavy Chain Antibody competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Single-Domain Heavy Chain Antibody market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Single-Domain Heavy Chain Antibody.
Chapter 13, to describe Single-Domain Heavy Chain Antibody research findings and conclusion.
Single-Domain Heavy Chain Antibody refers to a small antibody molecule in which a single variable domain can recognize and bind to an antigen. In industry usage, it is more commonly described as Single-Domain Antibody, VHH Antibody, or sdAb, covering camelid-derived VHH antibodies, shark-derived VNAR antibodies, and engineered human VH single-domain antibodies. Compared with conventional full-length IgG antibodies, these molecules are smaller, structurally simpler, and generally more stable, with good tissue penetration and strong engineering flexibility. They can be used in therapeutic biologics, diagnostic reagents, research antibodies, molecular imaging, cell therapy binding domains, and bispecific or multispecific antibody development. Key upstream inputs include antigen proteins or peptides, immunized animal resources, phage display libraries, yeast display libraries, synthetic antibody libraries, expression vectors, host cells, culture media, chromatography resins, conjugation reagents, and protein purification consumables. Major downstream customers include pharmaceutical companies, biotechnology companies, diagnostic companies, research service providers, universities, research institutes, and hospital laboratories. The global industry gross margin in 2025 is estimated at approximately 55%?75%.
The single-domain heavy chain antibody market is still in a stage of continuous platform validation and accelerating commercialization, with lower maturity than the conventional monoclonal antibody market but higher innovation activity. VHH, VNAR, and engineered human VH antibodies are gaining application momentum due to their small molecular size, good stability, engineering flexibility, and stronger tissue penetration. They are increasingly used in therapeutic biologics, diagnostic reagents, research antibodies, molecular imaging, and cell therapy engineering. Current market participants include innovative drug developers with proprietary platforms and clinical pipelines, as well as CROs and reagent companies providing antibody discovery, screening, humanization, affinity maturation, and protein expression services. The industry remains both platform-driven and project-driven.
From the demand side, therapeutic applications represent the highest long-term value area, especially in tumor immunology, immune-mediated inflammatory diseases, rare diseases, infectious diseases, and central nervous system delivery. Compared with conventional antibodies, single-domain antibodies are well suited for bispecific, multispecific, multivalent, and fusion protein formats, and can also serve as targeting domains for CAR-T, TCR-T, and other cell therapy products. At the same time, research and diagnostic applications provide a more stable demand base. Single-domain antibodies are well adapted for immunoassays, tissue staining, structural biology, live-cell imaging, and protein localization studies, supporting commercial demand before broader therapeutic commercialization.
Future development will focus on fully human platforms, multispecific design, half-life extension, AI-assisted screening, and high-throughput antibody library construction. The small size of single-domain antibodies is both an advantage and a limitation, as it can lead to faster in vivo clearance. As a result, albumin binding, Fc fusion, multivalent formatting, and PEGylation will remain important half-life extension strategies. With the integration of AI protein design, deep sequencing, synthetic antibody libraries, phage display, and yeast display technologies, discovery efficiency and developability assessment are expected to improve. Companies with strong capabilities in difficult-target screening, multi-format antibody engineering, CMC scale-up, and clinical translation will be better positioned in high-value therapeutic programs.
The main barriers include long clinical validation cycles, intellectual property constraints, immunogenicity control, manufacturing scale-up, and increasing service-level competition. Some VHH and VNAR molecules originate from non-human species, requiring sufficient humanization and immunogenicity assessment before therapeutic development. The short half-life associated with small molecular size also requires additional engineering, increasing R&D complexity. Meanwhile, as more CROs, research reagent suppliers, and platform companies enter VHH and sdAb discovery services, early-stage service pricing pressure may intensify. Overall, single-domain heavy chain antibodies are unlikely to simply replace conventional monoclonal antibodies, but they will continue to expand in differentiated scenarios such as difficult targets, multispecific formats, tissue penetration, imaging diagnostics, and cell therapy engineering.
This report is a detailed and comprehensive analysis for global Single-Domain Heavy Chain Antibody market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Single-Domain Heavy Chain Antibody market size and forecasts, in consumption value ($ Million), 2021-2032
Global Single-Domain Heavy Chain Antibody market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Single-Domain Heavy Chain Antibody market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Single-Domain Heavy Chain Antibody market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Single-Domain Heavy Chain Antibody
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Single-Domain Heavy Chain Antibody market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Camelid-Derived
- Shark-Derived
- Fully Human Platform
- Other
- VHH Antibody
- VNAR Antibody
- Human VH Antibody
- Other
- Oncology
- Immunology and Inflammation
- Neurology
- Other
- Pharmaceutical Companies
- Biotechnology Companies
- Other
- Sanofi
- MoonLake Immunotherapeutics
- Crescendo Biologics
- Ossianix
- Isogenica
- FairJourney Biologics
- Twist Bioscience
- RayBiotech
- Fortis Life Sciences
- AlpVHHs
- ProteoGenix
- Hybrigenics Services
- Sanyo Fine
- WuXi Biologics
- Harbour BioMed
- Biocytogen
- Sino Biological
- Biointron
- Novamab
- Creative Biolabs
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Single-Domain Heavy Chain Antibody product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Single-Domain Heavy Chain Antibody, with revenue, gross margin, and global market share of Single-Domain Heavy Chain Antibody from 2021 to 2026.
Chapter 3, the Single-Domain Heavy Chain Antibody competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Single-Domain Heavy Chain Antibody market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Single-Domain Heavy Chain Antibody.
Chapter 13, to describe Single-Domain Heavy Chain Antibody research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Single-Domain Heavy Chain Antibody by Type
1.3.1 Overview: Global Single-Domain Heavy Chain Antibody Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type in 2025
1.3.3 Camelid-Derived
1.3.4 Shark-Derived
1.3.5 Fully Human Platform
1.3.6 Other
1.4 Classification of Single-Domain Heavy Chain Antibody by Antibody Format
1.4.1 Overview: Global Single-Domain Heavy Chain Antibody Market Size by Antibody Format: 2021 Versus 2025 Versus 2032
1.4.2 Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Antibody Format in 2025
1.4.3 VHH Antibody
1.4.4 VNAR Antibody
1.4.5 Human VH Antibody
1.4.6 Other
1.5 Classification of Single-Domain Heavy Chain Antibody by Therapeutic Area
1.5.1 Overview: Global Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area: 2021 Versus 2025 Versus 2032
1.5.2 Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Therapeutic Area in 2025
1.5.3 Oncology
1.5.4 Immunology and Inflammation
1.5.5 Neurology
1.5.6 Other
1.6 Global Single-Domain Heavy Chain Antibody Market by Application
1.6.1 Overview: Global Single-Domain Heavy Chain Antibody Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Pharmaceutical Companies
1.6.3 Biotechnology Companies
1.6.4 Other
1.7 Global Single-Domain Heavy Chain Antibody Market Size & Forecast
1.8 Global Single-Domain Heavy Chain Antibody Market Size and Forecast by Region
1.8.1 Global Single-Domain Heavy Chain Antibody Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Single-Domain Heavy Chain Antibody Market Size by Region, (2021-2032)
1.8.3 North America Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
1.8.4 Europe Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
1.8.6 South America Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Single-Domain Heavy Chain Antibody Product and Solutions
2.1.4 Sanofi Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 MoonLake Immunotherapeutics
2.2.1 MoonLake Immunotherapeutics Details
2.2.2 MoonLake Immunotherapeutics Major Business
2.2.3 MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Product and Solutions
2.2.4 MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 MoonLake Immunotherapeutics Recent Developments and Future Plans
2.3 Crescendo Biologics
2.3.1 Crescendo Biologics Details
2.3.2 Crescendo Biologics Major Business
2.3.3 Crescendo Biologics Single-Domain Heavy Chain Antibody Product and Solutions
2.3.4 Crescendo Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Crescendo Biologics Recent Developments and Future Plans
2.4 Ossianix
2.4.1 Ossianix Details
2.4.2 Ossianix Major Business
2.4.3 Ossianix Single-Domain Heavy Chain Antibody Product and Solutions
2.4.4 Ossianix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Ossianix Recent Developments and Future Plans
2.5 Isogenica
2.5.1 Isogenica Details
2.5.2 Isogenica Major Business
2.5.3 Isogenica Single-Domain Heavy Chain Antibody Product and Solutions
2.5.4 Isogenica Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Isogenica Recent Developments and Future Plans
2.6 FairJourney Biologics
2.6.1 FairJourney Biologics Details
2.6.2 FairJourney Biologics Major Business
2.6.3 FairJourney Biologics Single-Domain Heavy Chain Antibody Product and Solutions
2.6.4 FairJourney Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 FairJourney Biologics Recent Developments and Future Plans
2.7 Twist Bioscience
2.7.1 Twist Bioscience Details
2.7.2 Twist Bioscience Major Business
2.7.3 Twist Bioscience Single-Domain Heavy Chain Antibody Product and Solutions
2.7.4 Twist Bioscience Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Twist Bioscience Recent Developments and Future Plans
2.8 RayBiotech
2.8.1 RayBiotech Details
2.8.2 RayBiotech Major Business
2.8.3 RayBiotech Single-Domain Heavy Chain Antibody Product and Solutions
2.8.4 RayBiotech Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 RayBiotech Recent Developments and Future Plans
2.9 Fortis Life Sciences
2.9.1 Fortis Life Sciences Details
2.9.2 Fortis Life Sciences Major Business
2.9.3 Fortis Life Sciences Single-Domain Heavy Chain Antibody Product and Solutions
2.9.4 Fortis Life Sciences Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Fortis Life Sciences Recent Developments and Future Plans
2.10 AlpVHHs
2.10.1 AlpVHHs Details
2.10.2 AlpVHHs Major Business
2.10.3 AlpVHHs Single-Domain Heavy Chain Antibody Product and Solutions
2.10.4 AlpVHHs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 AlpVHHs Recent Developments and Future Plans
2.11 ProteoGenix
2.11.1 ProteoGenix Details
2.11.2 ProteoGenix Major Business
2.11.3 ProteoGenix Single-Domain Heavy Chain Antibody Product and Solutions
2.11.4 ProteoGenix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 ProteoGenix Recent Developments and Future Plans
2.12 Hybrigenics Services
2.12.1 Hybrigenics Services Details
2.12.2 Hybrigenics Services Major Business
2.12.3 Hybrigenics Services Single-Domain Heavy Chain Antibody Product and Solutions
2.12.4 Hybrigenics Services Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Hybrigenics Services Recent Developments and Future Plans
2.13 Sanyo Fine
2.13.1 Sanyo Fine Details
2.13.2 Sanyo Fine Major Business
2.13.3 Sanyo Fine Single-Domain Heavy Chain Antibody Product and Solutions
2.13.4 Sanyo Fine Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Sanyo Fine Recent Developments and Future Plans
2.14 WuXi Biologics
2.14.1 WuXi Biologics Details
2.14.2 WuXi Biologics Major Business
2.14.3 WuXi Biologics Single-Domain Heavy Chain Antibody Product and Solutions
2.14.4 WuXi Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 WuXi Biologics Recent Developments and Future Plans
2.15 Harbour BioMed
2.15.1 Harbour BioMed Details
2.15.2 Harbour BioMed Major Business
2.15.3 Harbour BioMed Single-Domain Heavy Chain Antibody Product and Solutions
2.15.4 Harbour BioMed Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Harbour BioMed Recent Developments and Future Plans
2.16 Biocytogen
2.16.1 Biocytogen Details
2.16.2 Biocytogen Major Business
2.16.3 Biocytogen Single-Domain Heavy Chain Antibody Product and Solutions
2.16.4 Biocytogen Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Biocytogen Recent Developments and Future Plans
2.17 Sino Biological
2.17.1 Sino Biological Details
2.17.2 Sino Biological Major Business
2.17.3 Sino Biological Single-Domain Heavy Chain Antibody Product and Solutions
2.17.4 Sino Biological Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Sino Biological Recent Developments and Future Plans
2.18 Biointron
2.18.1 Biointron Details
2.18.2 Biointron Major Business
2.18.3 Biointron Single-Domain Heavy Chain Antibody Product and Solutions
2.18.4 Biointron Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Biointron Recent Developments and Future Plans
2.19 Novamab
2.19.1 Novamab Details
2.19.2 Novamab Major Business
2.19.3 Novamab Single-Domain Heavy Chain Antibody Product and Solutions
2.19.4 Novamab Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Novamab Recent Developments and Future Plans
2.20 Creative Biolabs
2.20.1 Creative Biolabs Details
2.20.2 Creative Biolabs Major Business
2.20.3 Creative Biolabs Single-Domain Heavy Chain Antibody Product and Solutions
2.20.4 Creative Biolabs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Creative Biolabs Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Single-Domain Heavy Chain Antibody Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Single-Domain Heavy Chain Antibody by Company Revenue
3.2.2 Top 3 Single-Domain Heavy Chain Antibody Players Market Share in 2025
3.2.3 Top 6 Single-Domain Heavy Chain Antibody Players Market Share in 2025
3.3 Single-Domain Heavy Chain Antibody Market: Overall Company Footprint Analysis
3.3.1 Single-Domain Heavy Chain Antibody Market: Region Footprint
3.3.2 Single-Domain Heavy Chain Antibody Market: Company Product Type Footprint
3.3.3 Single-Domain Heavy Chain Antibody Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Single-Domain Heavy Chain Antibody Consumption Value and Market Share by Type (2021-2026)
4.2 Global Single-Domain Heavy Chain Antibody Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2026)
5.2 Global Single-Domain Heavy Chain Antibody Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
6.2 North America Single-Domain Heavy Chain Antibody Market Size by Application (2021-2032)
6.3 North America Single-Domain Heavy Chain Antibody Market Size by Country
6.3.1 North America Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2032)
6.3.2 United States Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
6.3.3 Canada Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
6.3.4 Mexico Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
7.2 Europe Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2032)
7.3 Europe Single-Domain Heavy Chain Antibody Market Size by Country
7.3.1 Europe Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2032)
7.3.2 Germany Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7.3.3 France Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7.3.5 Russia Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7.3.6 Italy Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Single-Domain Heavy Chain Antibody Market Size by Region
8.3.1 Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2032)
8.3.2 China Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.3 Japan Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.4 South Korea Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.5 India Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.7 Australia Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
9.2 South America Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2032)
9.3 South America Single-Domain Heavy Chain Antibody Market Size by Country
9.3.1 South America Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2032)
9.3.2 Brazil Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
9.3.3 Argentina Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Single-Domain Heavy Chain Antibody Market Size by Country
10.3.1 Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2032)
10.3.2 Turkey Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
10.3.4 UAE Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Single-Domain Heavy Chain Antibody Market Drivers
11.2 Single-Domain Heavy Chain Antibody Market Restraints
11.3 Single-Domain Heavy Chain Antibody Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Single-Domain Heavy Chain Antibody Industry Chain
12.2 Single-Domain Heavy Chain Antibody Upstream Analysis
12.3 Single-Domain Heavy Chain Antibody Midstream Analysis
12.4 Single-Domain Heavy Chain Antibody Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Single-Domain Heavy Chain Antibody by Type
1.3.1 Overview: Global Single-Domain Heavy Chain Antibody Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type in 2025
1.3.3 Camelid-Derived
1.3.4 Shark-Derived
1.3.5 Fully Human Platform
1.3.6 Other
1.4 Classification of Single-Domain Heavy Chain Antibody by Antibody Format
1.4.1 Overview: Global Single-Domain Heavy Chain Antibody Market Size by Antibody Format: 2021 Versus 2025 Versus 2032
1.4.2 Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Antibody Format in 2025
1.4.3 VHH Antibody
1.4.4 VNAR Antibody
1.4.5 Human VH Antibody
1.4.6 Other
1.5 Classification of Single-Domain Heavy Chain Antibody by Therapeutic Area
1.5.1 Overview: Global Single-Domain Heavy Chain Antibody Market Size by Therapeutic Area: 2021 Versus 2025 Versus 2032
1.5.2 Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Therapeutic Area in 2025
1.5.3 Oncology
1.5.4 Immunology and Inflammation
1.5.5 Neurology
1.5.6 Other
1.6 Global Single-Domain Heavy Chain Antibody Market by Application
1.6.1 Overview: Global Single-Domain Heavy Chain Antibody Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Pharmaceutical Companies
1.6.3 Biotechnology Companies
1.6.4 Other
1.7 Global Single-Domain Heavy Chain Antibody Market Size & Forecast
1.8 Global Single-Domain Heavy Chain Antibody Market Size and Forecast by Region
1.8.1 Global Single-Domain Heavy Chain Antibody Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Single-Domain Heavy Chain Antibody Market Size by Region, (2021-2032)
1.8.3 North America Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
1.8.4 Europe Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
1.8.6 South America Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Single-Domain Heavy Chain Antibody Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Single-Domain Heavy Chain Antibody Product and Solutions
2.1.4 Sanofi Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 MoonLake Immunotherapeutics
2.2.1 MoonLake Immunotherapeutics Details
2.2.2 MoonLake Immunotherapeutics Major Business
2.2.3 MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Product and Solutions
2.2.4 MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 MoonLake Immunotherapeutics Recent Developments and Future Plans
2.3 Crescendo Biologics
2.3.1 Crescendo Biologics Details
2.3.2 Crescendo Biologics Major Business
2.3.3 Crescendo Biologics Single-Domain Heavy Chain Antibody Product and Solutions
2.3.4 Crescendo Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Crescendo Biologics Recent Developments and Future Plans
2.4 Ossianix
2.4.1 Ossianix Details
2.4.2 Ossianix Major Business
2.4.3 Ossianix Single-Domain Heavy Chain Antibody Product and Solutions
2.4.4 Ossianix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Ossianix Recent Developments and Future Plans
2.5 Isogenica
2.5.1 Isogenica Details
2.5.2 Isogenica Major Business
2.5.3 Isogenica Single-Domain Heavy Chain Antibody Product and Solutions
2.5.4 Isogenica Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Isogenica Recent Developments and Future Plans
2.6 FairJourney Biologics
2.6.1 FairJourney Biologics Details
2.6.2 FairJourney Biologics Major Business
2.6.3 FairJourney Biologics Single-Domain Heavy Chain Antibody Product and Solutions
2.6.4 FairJourney Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 FairJourney Biologics Recent Developments and Future Plans
2.7 Twist Bioscience
2.7.1 Twist Bioscience Details
2.7.2 Twist Bioscience Major Business
2.7.3 Twist Bioscience Single-Domain Heavy Chain Antibody Product and Solutions
2.7.4 Twist Bioscience Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Twist Bioscience Recent Developments and Future Plans
2.8 RayBiotech
2.8.1 RayBiotech Details
2.8.2 RayBiotech Major Business
2.8.3 RayBiotech Single-Domain Heavy Chain Antibody Product and Solutions
2.8.4 RayBiotech Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 RayBiotech Recent Developments and Future Plans
2.9 Fortis Life Sciences
2.9.1 Fortis Life Sciences Details
2.9.2 Fortis Life Sciences Major Business
2.9.3 Fortis Life Sciences Single-Domain Heavy Chain Antibody Product and Solutions
2.9.4 Fortis Life Sciences Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Fortis Life Sciences Recent Developments and Future Plans
2.10 AlpVHHs
2.10.1 AlpVHHs Details
2.10.2 AlpVHHs Major Business
2.10.3 AlpVHHs Single-Domain Heavy Chain Antibody Product and Solutions
2.10.4 AlpVHHs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 AlpVHHs Recent Developments and Future Plans
2.11 ProteoGenix
2.11.1 ProteoGenix Details
2.11.2 ProteoGenix Major Business
2.11.3 ProteoGenix Single-Domain Heavy Chain Antibody Product and Solutions
2.11.4 ProteoGenix Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 ProteoGenix Recent Developments and Future Plans
2.12 Hybrigenics Services
2.12.1 Hybrigenics Services Details
2.12.2 Hybrigenics Services Major Business
2.12.3 Hybrigenics Services Single-Domain Heavy Chain Antibody Product and Solutions
2.12.4 Hybrigenics Services Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Hybrigenics Services Recent Developments and Future Plans
2.13 Sanyo Fine
2.13.1 Sanyo Fine Details
2.13.2 Sanyo Fine Major Business
2.13.3 Sanyo Fine Single-Domain Heavy Chain Antibody Product and Solutions
2.13.4 Sanyo Fine Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Sanyo Fine Recent Developments and Future Plans
2.14 WuXi Biologics
2.14.1 WuXi Biologics Details
2.14.2 WuXi Biologics Major Business
2.14.3 WuXi Biologics Single-Domain Heavy Chain Antibody Product and Solutions
2.14.4 WuXi Biologics Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 WuXi Biologics Recent Developments and Future Plans
2.15 Harbour BioMed
2.15.1 Harbour BioMed Details
2.15.2 Harbour BioMed Major Business
2.15.3 Harbour BioMed Single-Domain Heavy Chain Antibody Product and Solutions
2.15.4 Harbour BioMed Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Harbour BioMed Recent Developments and Future Plans
2.16 Biocytogen
2.16.1 Biocytogen Details
2.16.2 Biocytogen Major Business
2.16.3 Biocytogen Single-Domain Heavy Chain Antibody Product and Solutions
2.16.4 Biocytogen Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Biocytogen Recent Developments and Future Plans
2.17 Sino Biological
2.17.1 Sino Biological Details
2.17.2 Sino Biological Major Business
2.17.3 Sino Biological Single-Domain Heavy Chain Antibody Product and Solutions
2.17.4 Sino Biological Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.17.5 Sino Biological Recent Developments and Future Plans
2.18 Biointron
2.18.1 Biointron Details
2.18.2 Biointron Major Business
2.18.3 Biointron Single-Domain Heavy Chain Antibody Product and Solutions
2.18.4 Biointron Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.18.5 Biointron Recent Developments and Future Plans
2.19 Novamab
2.19.1 Novamab Details
2.19.2 Novamab Major Business
2.19.3 Novamab Single-Domain Heavy Chain Antibody Product and Solutions
2.19.4 Novamab Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.19.5 Novamab Recent Developments and Future Plans
2.20 Creative Biolabs
2.20.1 Creative Biolabs Details
2.20.2 Creative Biolabs Major Business
2.20.3 Creative Biolabs Single-Domain Heavy Chain Antibody Product and Solutions
2.20.4 Creative Biolabs Single-Domain Heavy Chain Antibody Revenue, Gross Margin and Market Share (2021-2026)
2.20.5 Creative Biolabs Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Single-Domain Heavy Chain Antibody Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Single-Domain Heavy Chain Antibody by Company Revenue
3.2.2 Top 3 Single-Domain Heavy Chain Antibody Players Market Share in 2025
3.2.3 Top 6 Single-Domain Heavy Chain Antibody Players Market Share in 2025
3.3 Single-Domain Heavy Chain Antibody Market: Overall Company Footprint Analysis
3.3.1 Single-Domain Heavy Chain Antibody Market: Region Footprint
3.3.2 Single-Domain Heavy Chain Antibody Market: Company Product Type Footprint
3.3.3 Single-Domain Heavy Chain Antibody Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Single-Domain Heavy Chain Antibody Consumption Value and Market Share by Type (2021-2026)
4.2 Global Single-Domain Heavy Chain Antibody Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2026)
5.2 Global Single-Domain Heavy Chain Antibody Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
6.2 North America Single-Domain Heavy Chain Antibody Market Size by Application (2021-2032)
6.3 North America Single-Domain Heavy Chain Antibody Market Size by Country
6.3.1 North America Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2032)
6.3.2 United States Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
6.3.3 Canada Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
6.3.4 Mexico Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
7.2 Europe Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2032)
7.3 Europe Single-Domain Heavy Chain Antibody Market Size by Country
7.3.1 Europe Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2032)
7.3.2 Germany Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7.3.3 France Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7.3.5 Russia Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
7.3.6 Italy Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Single-Domain Heavy Chain Antibody Market Size by Region
8.3.1 Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2032)
8.3.2 China Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.3 Japan Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.4 South Korea Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.5 India Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
8.3.7 Australia Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
9.2 South America Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2032)
9.3 South America Single-Domain Heavy Chain Antibody Market Size by Country
9.3.1 South America Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2032)
9.3.2 Brazil Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
9.3.3 Argentina Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Single-Domain Heavy Chain Antibody Market Size by Country
10.3.1 Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2032)
10.3.2 Turkey Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
10.3.4 UAE Single-Domain Heavy Chain Antibody Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Single-Domain Heavy Chain Antibody Market Drivers
11.2 Single-Domain Heavy Chain Antibody Market Restraints
11.3 Single-Domain Heavy Chain Antibody Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Single-Domain Heavy Chain Antibody Industry Chain
12.2 Single-Domain Heavy Chain Antibody Upstream Analysis
12.3 Single-Domain Heavy Chain Antibody Midstream Analysis
12.4 Single-Domain Heavy Chain Antibody Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Single-Domain Heavy Chain Antibody Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Single-Domain Heavy Chain Antibody Consumption Value by Antibody Format, (USD Million), 2021 & 2025 & 2032
Table 3. Global Single-Domain Heavy Chain Antibody Consumption Value by Therapeutic Area, (USD Million), 2021 & 2025 & 2032
Table 4. Global Single-Domain Heavy Chain Antibody Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Single-Domain Heavy Chain Antibody Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Sanofi Company Information, Head Office, and Major Competitors
Table 8. Sanofi Major Business
Table 9. Sanofi Single-Domain Heavy Chain Antibody Product and Solutions
Table 10. Sanofi Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Sanofi Recent Developments and Future Plans
Table 12. MoonLake Immunotherapeutics Company Information, Head Office, and Major Competitors
Table 13. MoonLake Immunotherapeutics Major Business
Table 14. MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Product and Solutions
Table 15. MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. MoonLake Immunotherapeutics Recent Developments and Future Plans
Table 17. Crescendo Biologics Company Information, Head Office, and Major Competitors
Table 18. Crescendo Biologics Major Business
Table 19. Crescendo Biologics Single-Domain Heavy Chain Antibody Product and Solutions
Table 20. Crescendo Biologics Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Ossianix Company Information, Head Office, and Major Competitors
Table 22. Ossianix Major Business
Table 23. Ossianix Single-Domain Heavy Chain Antibody Product and Solutions
Table 24. Ossianix Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Ossianix Recent Developments and Future Plans
Table 26. Isogenica Company Information, Head Office, and Major Competitors
Table 27. Isogenica Major Business
Table 28. Isogenica Single-Domain Heavy Chain Antibody Product and Solutions
Table 29. Isogenica Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Isogenica Recent Developments and Future Plans
Table 31. FairJourney Biologics Company Information, Head Office, and Major Competitors
Table 32. FairJourney Biologics Major Business
Table 33. FairJourney Biologics Single-Domain Heavy Chain Antibody Product and Solutions
Table 34. FairJourney Biologics Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. FairJourney Biologics Recent Developments and Future Plans
Table 36. Twist Bioscience Company Information, Head Office, and Major Competitors
Table 37. Twist Bioscience Major Business
Table 38. Twist Bioscience Single-Domain Heavy Chain Antibody Product and Solutions
Table 39. Twist Bioscience Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Twist Bioscience Recent Developments and Future Plans
Table 41. RayBiotech Company Information, Head Office, and Major Competitors
Table 42. RayBiotech Major Business
Table 43. RayBiotech Single-Domain Heavy Chain Antibody Product and Solutions
Table 44. RayBiotech Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. RayBiotech Recent Developments and Future Plans
Table 46. Fortis Life Sciences Company Information, Head Office, and Major Competitors
Table 47. Fortis Life Sciences Major Business
Table 48. Fortis Life Sciences Single-Domain Heavy Chain Antibody Product and Solutions
Table 49. Fortis Life Sciences Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Fortis Life Sciences Recent Developments and Future Plans
Table 51. AlpVHHs Company Information, Head Office, and Major Competitors
Table 52. AlpVHHs Major Business
Table 53. AlpVHHs Single-Domain Heavy Chain Antibody Product and Solutions
Table 54. AlpVHHs Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. AlpVHHs Recent Developments and Future Plans
Table 56. ProteoGenix Company Information, Head Office, and Major Competitors
Table 57. ProteoGenix Major Business
Table 58. ProteoGenix Single-Domain Heavy Chain Antibody Product and Solutions
Table 59. ProteoGenix Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. ProteoGenix Recent Developments and Future Plans
Table 61. Hybrigenics Services Company Information, Head Office, and Major Competitors
Table 62. Hybrigenics Services Major Business
Table 63. Hybrigenics Services Single-Domain Heavy Chain Antibody Product and Solutions
Table 64. Hybrigenics Services Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Hybrigenics Services Recent Developments and Future Plans
Table 66. Sanyo Fine Company Information, Head Office, and Major Competitors
Table 67. Sanyo Fine Major Business
Table 68. Sanyo Fine Single-Domain Heavy Chain Antibody Product and Solutions
Table 69. Sanyo Fine Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Sanyo Fine Recent Developments and Future Plans
Table 71. WuXi Biologics Company Information, Head Office, and Major Competitors
Table 72. WuXi Biologics Major Business
Table 73. WuXi Biologics Single-Domain Heavy Chain Antibody Product and Solutions
Table 74. WuXi Biologics Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. WuXi Biologics Recent Developments and Future Plans
Table 76. Harbour BioMed Company Information, Head Office, and Major Competitors
Table 77. Harbour BioMed Major Business
Table 78. Harbour BioMed Single-Domain Heavy Chain Antibody Product and Solutions
Table 79. Harbour BioMed Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Harbour BioMed Recent Developments and Future Plans
Table 81. Biocytogen Company Information, Head Office, and Major Competitors
Table 82. Biocytogen Major Business
Table 83. Biocytogen Single-Domain Heavy Chain Antibody Product and Solutions
Table 84. Biocytogen Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Biocytogen Recent Developments and Future Plans
Table 86. Sino Biological Company Information, Head Office, and Major Competitors
Table 87. Sino Biological Major Business
Table 88. Sino Biological Single-Domain Heavy Chain Antibody Product and Solutions
Table 89. Sino Biological Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Sino Biological Recent Developments and Future Plans
Table 91. Biointron Company Information, Head Office, and Major Competitors
Table 92. Biointron Major Business
Table 93. Biointron Single-Domain Heavy Chain Antibody Product and Solutions
Table 94. Biointron Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. Biointron Recent Developments and Future Plans
Table 96. Novamab Company Information, Head Office, and Major Competitors
Table 97. Novamab Major Business
Table 98. Novamab Single-Domain Heavy Chain Antibody Product and Solutions
Table 99. Novamab Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. Novamab Recent Developments and Future Plans
Table 101. Creative Biolabs Company Information, Head Office, and Major Competitors
Table 102. Creative Biolabs Major Business
Table 103. Creative Biolabs Single-Domain Heavy Chain Antibody Product and Solutions
Table 104. Creative Biolabs Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. Creative Biolabs Recent Developments and Future Plans
Table 106. Global Single-Domain Heavy Chain Antibody Revenue (USD Million) by Players (2021-2026)
Table 107. Global Single-Domain Heavy Chain Antibody Revenue Share by Players (2021-2026)
Table 108. Breakdown of Single-Domain Heavy Chain Antibody by Company Type (Tier 1, Tier 2, and Tier 3)
Table 109. Market Position of Players in Single-Domain Heavy Chain Antibody, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 110. Head Office of Key Single-Domain Heavy Chain Antibody Players
Table 111. Single-Domain Heavy Chain Antibody Market: Company Product Type Footprint
Table 112. Single-Domain Heavy Chain Antibody Market: Company Product Application Footprint
Table 113. Single-Domain Heavy Chain Antibody New Market Entrants and Barriers to Market Entry
Table 114. Single-Domain Heavy Chain Antibody Mergers, Acquisition, Agreements, and Collaborations
Table 115. Global Single-Domain Heavy Chain Antibody Consumption Value (USD Million) by Type (2021-2026)
Table 116. Global Single-Domain Heavy Chain Antibody Consumption Value Share by Type (2021-2026)
Table 117. Global Single-Domain Heavy Chain Antibody Consumption Value Forecast by Type (2027-2032)
Table 118. Global Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026)
Table 119. Global Single-Domain Heavy Chain Antibody Consumption Value Forecast by Application (2027-2032)
Table 120. North America Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 121. North America Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 122. North America Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 123. North America Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 124. North America Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2026) & (USD Million)
Table 125. North America Single-Domain Heavy Chain Antibody Consumption Value by Country (2027-2032) & (USD Million)
Table 126. Europe Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 127. Europe Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 128. Europe Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 129. Europe Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 130. Europe Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2026) & (USD Million)
Table 131. Europe Single-Domain Heavy Chain Antibody Consumption Value by Country (2027-2032) & (USD Million)
Table 132. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 133. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 134. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 135. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 136. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2026) & (USD Million)
Table 137. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Region (2027-2032) & (USD Million)
Table 138. South America Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 139. South America Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 140. South America Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 141. South America Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 142. South America Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2026) & (USD Million)
Table 143. South America Single-Domain Heavy Chain Antibody Consumption Value by Country (2027-2032) & (USD Million)
Table 144. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 145. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 146. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 147. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 148. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2026) & (USD Million)
Table 149. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Country (2027-2032) & (USD Million)
Table 150. Global Key Players of Single-Domain Heavy Chain Antibody Upstream (Raw Materials)
Table 151. Global Single-Domain Heavy Chain Antibody Typical Customers
Table 1. Global Single-Domain Heavy Chain Antibody Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Single-Domain Heavy Chain Antibody Consumption Value by Antibody Format, (USD Million), 2021 & 2025 & 2032
Table 3. Global Single-Domain Heavy Chain Antibody Consumption Value by Therapeutic Area, (USD Million), 2021 & 2025 & 2032
Table 4. Global Single-Domain Heavy Chain Antibody Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Single-Domain Heavy Chain Antibody Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Sanofi Company Information, Head Office, and Major Competitors
Table 8. Sanofi Major Business
Table 9. Sanofi Single-Domain Heavy Chain Antibody Product and Solutions
Table 10. Sanofi Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Sanofi Recent Developments and Future Plans
Table 12. MoonLake Immunotherapeutics Company Information, Head Office, and Major Competitors
Table 13. MoonLake Immunotherapeutics Major Business
Table 14. MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Product and Solutions
Table 15. MoonLake Immunotherapeutics Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. MoonLake Immunotherapeutics Recent Developments and Future Plans
Table 17. Crescendo Biologics Company Information, Head Office, and Major Competitors
Table 18. Crescendo Biologics Major Business
Table 19. Crescendo Biologics Single-Domain Heavy Chain Antibody Product and Solutions
Table 20. Crescendo Biologics Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Ossianix Company Information, Head Office, and Major Competitors
Table 22. Ossianix Major Business
Table 23. Ossianix Single-Domain Heavy Chain Antibody Product and Solutions
Table 24. Ossianix Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Ossianix Recent Developments and Future Plans
Table 26. Isogenica Company Information, Head Office, and Major Competitors
Table 27. Isogenica Major Business
Table 28. Isogenica Single-Domain Heavy Chain Antibody Product and Solutions
Table 29. Isogenica Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Isogenica Recent Developments and Future Plans
Table 31. FairJourney Biologics Company Information, Head Office, and Major Competitors
Table 32. FairJourney Biologics Major Business
Table 33. FairJourney Biologics Single-Domain Heavy Chain Antibody Product and Solutions
Table 34. FairJourney Biologics Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. FairJourney Biologics Recent Developments and Future Plans
Table 36. Twist Bioscience Company Information, Head Office, and Major Competitors
Table 37. Twist Bioscience Major Business
Table 38. Twist Bioscience Single-Domain Heavy Chain Antibody Product and Solutions
Table 39. Twist Bioscience Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Twist Bioscience Recent Developments and Future Plans
Table 41. RayBiotech Company Information, Head Office, and Major Competitors
Table 42. RayBiotech Major Business
Table 43. RayBiotech Single-Domain Heavy Chain Antibody Product and Solutions
Table 44. RayBiotech Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. RayBiotech Recent Developments and Future Plans
Table 46. Fortis Life Sciences Company Information, Head Office, and Major Competitors
Table 47. Fortis Life Sciences Major Business
Table 48. Fortis Life Sciences Single-Domain Heavy Chain Antibody Product and Solutions
Table 49. Fortis Life Sciences Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Fortis Life Sciences Recent Developments and Future Plans
Table 51. AlpVHHs Company Information, Head Office, and Major Competitors
Table 52. AlpVHHs Major Business
Table 53. AlpVHHs Single-Domain Heavy Chain Antibody Product and Solutions
Table 54. AlpVHHs Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. AlpVHHs Recent Developments and Future Plans
Table 56. ProteoGenix Company Information, Head Office, and Major Competitors
Table 57. ProteoGenix Major Business
Table 58. ProteoGenix Single-Domain Heavy Chain Antibody Product and Solutions
Table 59. ProteoGenix Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. ProteoGenix Recent Developments and Future Plans
Table 61. Hybrigenics Services Company Information, Head Office, and Major Competitors
Table 62. Hybrigenics Services Major Business
Table 63. Hybrigenics Services Single-Domain Heavy Chain Antibody Product and Solutions
Table 64. Hybrigenics Services Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Hybrigenics Services Recent Developments and Future Plans
Table 66. Sanyo Fine Company Information, Head Office, and Major Competitors
Table 67. Sanyo Fine Major Business
Table 68. Sanyo Fine Single-Domain Heavy Chain Antibody Product and Solutions
Table 69. Sanyo Fine Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Sanyo Fine Recent Developments and Future Plans
Table 71. WuXi Biologics Company Information, Head Office, and Major Competitors
Table 72. WuXi Biologics Major Business
Table 73. WuXi Biologics Single-Domain Heavy Chain Antibody Product and Solutions
Table 74. WuXi Biologics Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. WuXi Biologics Recent Developments and Future Plans
Table 76. Harbour BioMed Company Information, Head Office, and Major Competitors
Table 77. Harbour BioMed Major Business
Table 78. Harbour BioMed Single-Domain Heavy Chain Antibody Product and Solutions
Table 79. Harbour BioMed Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Harbour BioMed Recent Developments and Future Plans
Table 81. Biocytogen Company Information, Head Office, and Major Competitors
Table 82. Biocytogen Major Business
Table 83. Biocytogen Single-Domain Heavy Chain Antibody Product and Solutions
Table 84. Biocytogen Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Biocytogen Recent Developments and Future Plans
Table 86. Sino Biological Company Information, Head Office, and Major Competitors
Table 87. Sino Biological Major Business
Table 88. Sino Biological Single-Domain Heavy Chain Antibody Product and Solutions
Table 89. Sino Biological Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 90. Sino Biological Recent Developments and Future Plans
Table 91. Biointron Company Information, Head Office, and Major Competitors
Table 92. Biointron Major Business
Table 93. Biointron Single-Domain Heavy Chain Antibody Product and Solutions
Table 94. Biointron Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 95. Biointron Recent Developments and Future Plans
Table 96. Novamab Company Information, Head Office, and Major Competitors
Table 97. Novamab Major Business
Table 98. Novamab Single-Domain Heavy Chain Antibody Product and Solutions
Table 99. Novamab Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 100. Novamab Recent Developments and Future Plans
Table 101. Creative Biolabs Company Information, Head Office, and Major Competitors
Table 102. Creative Biolabs Major Business
Table 103. Creative Biolabs Single-Domain Heavy Chain Antibody Product and Solutions
Table 104. Creative Biolabs Single-Domain Heavy Chain Antibody Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 105. Creative Biolabs Recent Developments and Future Plans
Table 106. Global Single-Domain Heavy Chain Antibody Revenue (USD Million) by Players (2021-2026)
Table 107. Global Single-Domain Heavy Chain Antibody Revenue Share by Players (2021-2026)
Table 108. Breakdown of Single-Domain Heavy Chain Antibody by Company Type (Tier 1, Tier 2, and Tier 3)
Table 109. Market Position of Players in Single-Domain Heavy Chain Antibody, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 110. Head Office of Key Single-Domain Heavy Chain Antibody Players
Table 111. Single-Domain Heavy Chain Antibody Market: Company Product Type Footprint
Table 112. Single-Domain Heavy Chain Antibody Market: Company Product Application Footprint
Table 113. Single-Domain Heavy Chain Antibody New Market Entrants and Barriers to Market Entry
Table 114. Single-Domain Heavy Chain Antibody Mergers, Acquisition, Agreements, and Collaborations
Table 115. Global Single-Domain Heavy Chain Antibody Consumption Value (USD Million) by Type (2021-2026)
Table 116. Global Single-Domain Heavy Chain Antibody Consumption Value Share by Type (2021-2026)
Table 117. Global Single-Domain Heavy Chain Antibody Consumption Value Forecast by Type (2027-2032)
Table 118. Global Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026)
Table 119. Global Single-Domain Heavy Chain Antibody Consumption Value Forecast by Application (2027-2032)
Table 120. North America Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 121. North America Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 122. North America Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 123. North America Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 124. North America Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2026) & (USD Million)
Table 125. North America Single-Domain Heavy Chain Antibody Consumption Value by Country (2027-2032) & (USD Million)
Table 126. Europe Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 127. Europe Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 128. Europe Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 129. Europe Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 130. Europe Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2026) & (USD Million)
Table 131. Europe Single-Domain Heavy Chain Antibody Consumption Value by Country (2027-2032) & (USD Million)
Table 132. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 133. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 134. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 135. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 136. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Region (2021-2026) & (USD Million)
Table 137. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value by Region (2027-2032) & (USD Million)
Table 138. South America Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 139. South America Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 140. South America Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 141. South America Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 142. South America Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2026) & (USD Million)
Table 143. South America Single-Domain Heavy Chain Antibody Consumption Value by Country (2027-2032) & (USD Million)
Table 144. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Type (2021-2026) & (USD Million)
Table 145. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Type (2027-2032) & (USD Million)
Table 146. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Application (2021-2026) & (USD Million)
Table 147. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Application (2027-2032) & (USD Million)
Table 148. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Country (2021-2026) & (USD Million)
Table 149. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value by Country (2027-2032) & (USD Million)
Table 150. Global Key Players of Single-Domain Heavy Chain Antibody Upstream (Raw Materials)
Table 151. Global Single-Domain Heavy Chain Antibody Typical Customers
LIST OF FIGURES
Figure 1. Single-Domain Heavy Chain Antibody Picture
Figure 2. Global Single-Domain Heavy Chain Antibody Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type in 2025
Figure 4. Camelid-Derived
Figure 5. Shark-Derived
Figure 6. Fully Human Platform
Figure 7. Other
Figure 8. Global Single-Domain Heavy Chain Antibody Consumption Value by Antibody Format, (USD Million), 2021 & 2025 & 2032
Figure 9. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Antibody Format in 2025
Figure 10. VHH Antibody
Figure 11. VNAR Antibody
Figure 12. Human VH Antibody
Figure 13. Other
Figure 14. Global Single-Domain Heavy Chain Antibody Consumption Value by Therapeutic Area, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Therapeutic Area in 2025
Figure 16. Oncology
Figure 17. Immunology and Inflammation
Figure 18. Neurology
Figure 19. Other
Figure 20. Global Single-Domain Heavy Chain Antibody Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 21. Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application in 2025
Figure 22. Pharmaceutical Companies Picture
Figure 23. Biotechnology Companies Picture
Figure 24. Other Picture
Figure 25. Global Single-Domain Heavy Chain Antibody Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 26. Global Single-Domain Heavy Chain Antibody Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 27. Global Market Single-Domain Heavy Chain Antibody Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 28. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Region (2021-2032)
Figure 29. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Region in 2025
Figure 30. North America Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 31. Europe Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 32. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 33. South America Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 34. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 35. Company Three Recent Developments and Future Plans
Figure 36. Global Single-Domain Heavy Chain Antibody Revenue Share by Players in 2025
Figure 37. Single-Domain Heavy Chain Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 38. Market Share of Single-Domain Heavy Chain Antibody by Player Revenue in 2025
Figure 39. Top 3 Single-Domain Heavy Chain Antibody Players Market Share in 2025
Figure 40. Top 6 Single-Domain Heavy Chain Antibody Players Market Share in 2025
Figure 41. Global Single-Domain Heavy Chain Antibody Consumption Value Share by Type (2021-2026)
Figure 42. Global Single-Domain Heavy Chain Antibody Market Share Forecast by Type (2027-2032)
Figure 43. Global Single-Domain Heavy Chain Antibody Consumption Value Share by Application (2021-2026)
Figure 44. Global Single-Domain Heavy Chain Antibody Market Share Forecast by Application (2027-2032)
Figure 45. North America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 46. North America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 47. North America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Country (2021-2032)
Figure 48. United States Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 49. Canada Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 50. Mexico Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 52. Europe Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 53. Europe Single-Domain Heavy Chain Antibody Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 55. France Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 60. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 61. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value Market Share by Region (2021-2032)
Figure 62. China Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 63. Japan Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 64. South Korea Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 65. India Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 66. Southeast Asia Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 67. Australia Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 68. South America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 69. South America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 70. South America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Country (2021-2032)
Figure 71. Brazil Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 72. Argentina Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 73. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 74. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 75. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value Market Share by Country (2021-2032)
Figure 76. Turkey Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 77. Saudi Arabia Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 78. UAE Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 79. Single-Domain Heavy Chain Antibody Market Drivers
Figure 80. Single-Domain Heavy Chain Antibody Market Restraints
Figure 81. Single-Domain Heavy Chain Antibody Market Trends
Figure 82. Porters Five Forces Analysis
Figure 83. Single-Domain Heavy Chain Antibody Industrial Chain
Figure 84. Methodology
Figure 85. Research Process and Data Source
Figure 1. Single-Domain Heavy Chain Antibody Picture
Figure 2. Global Single-Domain Heavy Chain Antibody Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type in 2025
Figure 4. Camelid-Derived
Figure 5. Shark-Derived
Figure 6. Fully Human Platform
Figure 7. Other
Figure 8. Global Single-Domain Heavy Chain Antibody Consumption Value by Antibody Format, (USD Million), 2021 & 2025 & 2032
Figure 9. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Antibody Format in 2025
Figure 10. VHH Antibody
Figure 11. VNAR Antibody
Figure 12. Human VH Antibody
Figure 13. Other
Figure 14. Global Single-Domain Heavy Chain Antibody Consumption Value by Therapeutic Area, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Therapeutic Area in 2025
Figure 16. Oncology
Figure 17. Immunology and Inflammation
Figure 18. Neurology
Figure 19. Other
Figure 20. Global Single-Domain Heavy Chain Antibody Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 21. Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application in 2025
Figure 22. Pharmaceutical Companies Picture
Figure 23. Biotechnology Companies Picture
Figure 24. Other Picture
Figure 25. Global Single-Domain Heavy Chain Antibody Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 26. Global Single-Domain Heavy Chain Antibody Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 27. Global Market Single-Domain Heavy Chain Antibody Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 28. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Region (2021-2032)
Figure 29. Global Single-Domain Heavy Chain Antibody Consumption Value Market Share by Region in 2025
Figure 30. North America Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 31. Europe Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 32. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 33. South America Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 34. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 35. Company Three Recent Developments and Future Plans
Figure 36. Global Single-Domain Heavy Chain Antibody Revenue Share by Players in 2025
Figure 37. Single-Domain Heavy Chain Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 38. Market Share of Single-Domain Heavy Chain Antibody by Player Revenue in 2025
Figure 39. Top 3 Single-Domain Heavy Chain Antibody Players Market Share in 2025
Figure 40. Top 6 Single-Domain Heavy Chain Antibody Players Market Share in 2025
Figure 41. Global Single-Domain Heavy Chain Antibody Consumption Value Share by Type (2021-2026)
Figure 42. Global Single-Domain Heavy Chain Antibody Market Share Forecast by Type (2027-2032)
Figure 43. Global Single-Domain Heavy Chain Antibody Consumption Value Share by Application (2021-2026)
Figure 44. Global Single-Domain Heavy Chain Antibody Market Share Forecast by Application (2027-2032)
Figure 45. North America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 46. North America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 47. North America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Country (2021-2032)
Figure 48. United States Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 49. Canada Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 50. Mexico Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 51. Europe Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 52. Europe Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 53. Europe Single-Domain Heavy Chain Antibody Consumption Value Market Share by Country (2021-2032)
Figure 54. Germany Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 55. France Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 56. United Kingdom Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 57. Russia Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 58. Italy Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 59. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 60. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 61. Asia-Pacific Single-Domain Heavy Chain Antibody Consumption Value Market Share by Region (2021-2032)
Figure 62. China Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 63. Japan Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 64. South Korea Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 65. India Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 66. Southeast Asia Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 67. Australia Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 68. South America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 69. South America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 70. South America Single-Domain Heavy Chain Antibody Consumption Value Market Share by Country (2021-2032)
Figure 71. Brazil Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 72. Argentina Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 73. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value Market Share by Type (2021-2032)
Figure 74. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value Market Share by Application (2021-2032)
Figure 75. Middle East & Africa Single-Domain Heavy Chain Antibody Consumption Value Market Share by Country (2021-2032)
Figure 76. Turkey Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 77. Saudi Arabia Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 78. UAE Single-Domain Heavy Chain Antibody Consumption Value (2021-2032) & (USD Million)
Figure 79. Single-Domain Heavy Chain Antibody Market Drivers
Figure 80. Single-Domain Heavy Chain Antibody Market Restraints
Figure 81. Single-Domain Heavy Chain Antibody Market Trends
Figure 82. Porters Five Forces Analysis
Figure 83. Single-Domain Heavy Chain Antibody Industrial Chain
Figure 84. Methodology
Figure 85. Research Process and Data Source
